retatrutide approved by fda Triple-agonist (GLP1++) is not yet FDA-approved and is projected to be submitted for approval in late 2026, with commercial release expected between late 2026 and 2028. "Among the heaviest patients in Will the FDA approve retatrutide?

G protein-coupled estrogen receptor in energy homeostasis and obesity pathogenesis

doi.org/10.1038/newbio243085a0 Sikiri, P., et al

MeAgain helps by keeping meals, water, protein, the weekly shot, and custom notes in one place instead of scattering them across a food app, a notes app, and your memory

For the first New Year, I am not having weight loss as a goal

PRODUCT FACTS: Biotin 600 mcg --- 200%

The cAMP signaling pathway potentially enhances melanin production and deposition, which serves as a natural defense against UV penetration and facilitates nucleotide excision repair (NER), a crucial process for potentially removing UV-induced DNA lesions and averting mutagenesis